Pegcetacoplan (Empaveli) was approved by the U.S. Food and Drug Administration (FDA) on May 14, 2021, for the treatment of PNH.

Loncastuximab tesirine (Zynlonta) was approved by the U.S. Food and Drug Administration (FDA) on April 23, 2021.

Viloxazine (Qelbree) was approved by the U.S. Food and Drug Administration (FDA) on April 2, 2021.

Dasiglucagon (Zegalogue) was approved by the U.S. Food and Drug Administration (FDA) on March 22, 2021.

Ponvory (ponesimod) was approved by the U.S. Food and Drug Administration (FDA) on March 18, 2021.

Abecma (idecabtagene vicleucel) received approval from the U.S. Food and Drug Administration (FDA) on March 26, 2021.

Azstarys was approved by the U.S. Food and Drug Administration (FDA) on March 2, 2021.

Fosdenopterin (Nulibry) was approved by the U.S. Food and Drug Administration (FDA) on February 26, 2021.

Melphalan flufenamide (Pepaxto) was approved by the U.S. Food and Drug Administration (FDA) on February 26, 2021.

Casimersen was approved by the U.S. Food and Drug Administration (FDA) on February 25, 2021.

Trilaciclib was approved by the U.S. Food and Drug Administration (FDA) on February 12, 2021.

Evinacumab was approved by the U.S. Food and Drug Administration (FDA) on February 11, 2021.